11:21 AM EST, 01/07/2025 (MT Newswires) -- Annovis Bio ( ANVS ) said Tuesday that the US Food and Drug Administration has approved its revised protocol for a pivotal phase 3 trial of buntanetap as potential treatment for Alzheimer's disease.

Instead of conducting two separate trials, the new protocol combines a six-month symptomatic study and an 18-month disease-modifying study into one integrated 6/18-month trial, which begins this month, the company said.

Shares of the company were down 4.7% in recent trading.

Price: 5.10, Change: -0.25, Percent Change: -4.67